Prevalence of human papillomavirus types in invasive cervical cancers from seven US cancer registries prior to vaccine introduction
Published Date:Apr 2014
Source:J Low Genit Tract Dis. 18(2):182-189.
Pubmed Central ID:PMC4294218
Funding:1U58DP000807-3/DP/NCCDPHP CDC HHS/United States
5U58DP000769-5/DP/NCCDPHP CDC HHS/United States
5U58DP000810-5/DP/NCCDPHP CDC HHS/United States
5U58DP000812-5/DP/NCCDPHP CDC HHS/United States
5U58DP000844-5/DP/NCCDPHP CDC HHS/United States
N01 PC035137/PC/NCI NIH HHS/United States
N01-PC-2010-00035/PC/NCI NIH HHS/United States
N01-PC-35137/PC/NCI NIH HHS/United States
N01-PC-35139/PC/NCI NIH HHS/United States
N01-PC-35143/PC/NCI NIH HHS/United States
P30 CA071789/CA/NCI NIH HHS/United States
P30 CA086862/CA/NCI NIH HHS/United States
P30 CA177558/CA/NCI NIH HHS/United States
P30 ES005605/ES/NIEHS NIH HHS/United States
We conducted a baseline study of human papillomavirus (HPV) type prevalence in invasive cervical cancers (ICC) using data from seven cancer registries (CR) in the US. Cases were diagnosed between 1994 and 2005, before the implementation of the HPV vaccines.
Materials and Methods
CRs from Florida, Kentucky, Louisiana, Michigan, Hawaii, Iowa and Los Angeles, California identified eligible ICC cases, and obtained sections from representative blocks of archived tumor specimens for DNA extraction. All extracts were assayed by Linear Array and if inadequate or HPV negative, re-tested with INNO-LiPA Genotype test. Clinical and demographic factors were obtained from the CRs and merged with the HPV typing data to analyze factors associated with different types and with HPV negativity.
A total of 777 ICCs were included in this analysis, with broad geographic, age and race distribution. Overall, HPV was detected in 91% of cases, including 51% HPV16, 16% HPV18 (HPV16 negative), and 24% other oncogenic and rare types. After HPV16 and 18, the most common types were 45, 33, 31, 35 and 52. Older age and non-squamous histology were associated with HPV negative typing.
This study provides baseline pre-vaccine HPV types for post-vaccine ICC surveillance in the future. HPV16 and/or 18 were found in 67% of ICCs, indicating the potential for vaccines to prevent a significant number of cervical cancers.
You May Also Like: